Promazine

Promazine
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a600010
Drug class	Typical antipsychotic
ATC code	N05AA03 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances);
Pharmacokinetic data
Protein binding	94%
Elimination half-life	20-40 hr
Identifiers
	IUPAC name N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine;
CAS Number	58-40-2 ;
PubChem CID	4926;
IUPHAR/BPS	7281;
DrugBank	DB00420 ;
ChemSpider	4757 ;
UNII	O9M39HTM5W;
KEGG	D08430;
ChEBI	CHEBI:8459 ;
ChEMBL	ChEMBL564 ;
CompTox Dashboard (EPA)	DTXSID2023517 ;
ECHA InfoCard	100.000.347
Chemical and physical data
Formula	C17H20N2S
Molar mass	284.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCCN1c2ccccc2Sc3c1cccc3;
	InChI InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3 ; Key:ZGUGWUXLJSTTMA-UHFFFAOYSA-N ;
	(verify)

Promazine (brand name Sparine among others), is used as a short-term add-on treatment for psychomotor agitation. Its approved uses in people is limited, but is used as a tranquilizer in veterinary medicine. It has weak antipsychotic effects but is generally not used to treat psychoses.

It acts similar to chlorpromazine and causes sedation. It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon. It belongs to the typical antipsychotic and phenothiazine class of drugs.

Promazine was approved for medical use in the United States in the 1950s, although it is no longer commercially available there.